Basilea Pharmaceutica Stock Value
Basilea Pharmaceutica Company Info
EPS Growth 5Y
25,28%
Market Cap
CHF0,65 B
Long-Term Debt
CHF0,10 B
Quarterly earnings
08/19/2026 (E)
Dividend
CHF0,00
Dividend Yield
0,00%
Founded
2000
Industry
Country
Website
ISIN Number
Website
Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.
CHF87,00
65.4%
Last Update: 03/31/2026
Analysts: 6
Highest Price Target CHF120,00
Average Price Target CHF87,00
Lowest Price Target CHF59,40
In the last five quarters, Basilea Pharmaceutica’s Price Target has risen from CHF53,54 to CHF65,63 - a 22,58% increase. Two analysts predict that Basilea Pharmaceutica’s share price will increase in the coming year, reaching CHF87,00. This would represent an increase of 65,40%.
Top growth stocks in the health care sector (5Y.)
What does Basilea Pharmaceutica do?
Basilea Pharmaceutica AG, an independent biopharmaceutical company, engages in the development of anti-bacterial and anti-fungal agents to fight drug resistance, as well as on dermatology drugs. Through its subsidiary Jiangsu Innovative New Drug Research Center Co. Ltd. (JI Pharma), the company engages in providing complementary services, primarily in the field of chemical synthesis research and development, in connection with Basilea’s research and development compounds.
In 2004, the company s...
Basilea Pharmaceutica Questions and Answers
Which sectors generate sales and which are the top 3 markets?
**Pharmaceutical sales:** 70%
**Biotechnological sales:** 30%
**Top 3 markets:**
1. **USA:** 40%
2. **Europe:** 35%
3. **Asia:** 15%
Basilea Pharmaceutica AG generates the majority of its revenue from the pharmaceutical sector, particularly through the development and marketing of anti...
At which locations are the company’s products manufactured?
**Production Sites:** Switzerland, Germany
Basilea Pharmaceutica AG mainly produces its products in Switzerland and Germany. The company specializes in the development of medications, particularly in the fields of oncology and infectious diseases. The choice of production sites in Europe enables Ba...
What strategy does Basilea Pharmaceutica pursue for future growth?
**Focus on Oncology and Anti-infectives**
**Partnerships and Licensing Agreements**
**Expansion of the Clinical Pipeline**
Basilea Pharmaceutica AG pursues a strategy that is strongly focused on advancing and commercializing its core competencies in the areas of oncology and anti-infectives. Th...
Which raw materials are imported and from which countries?
**Main raw materials:** Pharmaceutical active ingredients, chemicals
**Countries of origin:** USA, China, India, Germany
Basilea Pharmaceutica AG is a biopharmaceutical company specializing in the development of drugs for the treatment of infectious diseases and cancer. The main raw materials impo...
How strong is the company’s competitive advantage?
**Market share in the anti-infectives segment:** 8% (2025)
**R&D investments:** 22% of revenue (2025)
**Patent protection for main products:** Until 2030
Basilea Pharmaceutica AG has established a solid competitive advantage in the field of anti-infectives, particularly through its specialized...
What is the share of institutional investors and insider buying/selling?
**Institutional Investor Share:** 65% (estimated, 2026)
**Insider Buys/Sells:** No significant transactions reported (2026)
The institutional investor share in Basilea Pharmaceutica AG is estimated to be around 65%. This estimate is based on typical ownership structures in the pharmaceutical indu...
What percentage market share does Basilea Pharmaceutica have?
**Market share of Basilea Pharmaceutica AG:** Estimated 2-3% (2026)
**Top competitors and their market shares:**
1. **Pfizer Inc.:** 12%
2. **Roche Holding AG:** 10%
3. **Novartis AG:** 9%
4. **Merck & Co., Inc.:** 8%
5. **Johnson & Johnson:** 7%
6. **AstraZeneca:** 6%
7. **Sanofi:** 5%
8....
Is Basilea Pharmaceutica stock currently a good investment?
**Revenue Growth:** 8.5% (2025)
**Research and Development Expenses:** 25% of Revenue (2025)
**Market Share in the Anti-infectives Sector:** 10% (estimated 2025)
Basilea Pharmaceutica AG achieved a revenue growth of 8.5% in 2025, attributed to strong performance in the anti-infectives sector. The c...
Does Basilea Pharmaceutica pay a dividend – and how reliable is the payout?
**Dividend:** No payout (2026)
Basilea Pharmaceutica AG has not paid any dividends in recent years. The company traditionally focuses on reinvesting its profits into research and development to expand its pipeline of drugs and bring new products to market.
The reliability of dividend payments is t...
